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Alzheimer's disease (AD) is one of the most common dementing disorders and has profound medical and social consequences. The initiating
molecular event is unknown, and its pathophysiology is highly complex. However, free radical injury appears to be a fundamental process
contributing to the neuronal death seen in this disorder, and many studies using surrogate markers of oxidative damage have provided evidence
supporting this hypothesis. Various compounds with antioxidant ability attenuated the oxidative stress induced by amyloid β-protein (Aβ) in
studies done in vitro and in vivo. Moreover, various antioxidants have been reported to inhibit the formation and extension of β-amyloid fibrils
(fAβ), as well as to destabilize preformed fAβ in vitro. In cell culture experiments, destabilized fAβ were suggested to be less toxic than intact
fAβ. In transgenic mice model studies, some antioxidant coumpounds reduced plaque burden in vivo. In this article, we review the recent
advances in the research on the antioxidants that inhibit the formation of fAβ, as well as destabilize preformed fAβ. Although the mechanisms by
which these compounds inhibit fAβ formation from Aβ, and destabilize preformed fAβ are still unclear, they could be key molecules for the
development of preventives and therapeutics for AD.
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While oxidative stress refers to the undue oxidation of bio-
molecules leading to cellular damage, and it occurs by reactive
oxygen species (ROS) [1], the histopathological and the ex-
perimental evidence that support the impact of oxidation on the
pathogenesis of Alzheimer's disease (AD) (oxidative-stress-
hypothesis) is increasing [2,3]. Cells in the brains of AD patients
exhibit abnormally high amounts of oxidatively modified pro-
teins, lipids and DNA; such free radical-mediated molecular
damage is particularly prominent in the environment of senile
plaques and in neurofibrillary tangle-bearing neurons, suggesting
roles for ROS in amyloid-mediated neuronal damage and
neurofibrillary pathologies [4]. Several sources of ROS in AD
have been proposed, with amyloid β-protein (Aβ) and redox-⁎ Corresponding author. Tel.: +81 76 265 2290; fax: +81 76 234 4253.
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doi:10.1016/j.bbadis.2006.03.002active metals such as Fe2+ or Cu+ being two such sources [4–7].
During the process of aggregation Aβ generates hydrogen
peroxide, a process that requires oxygen and that is greatly
potentiated by Fe2+ and Cu+ [8,9]. Lipid peroxidation induced by
Aβ impairs the function of ion-motive ATPases, glucose and
glutamate transporters, and also GTP-binding proteins as the
results of covalent modification of the proteins by the aldehyde
4-hydroxynonenal [10]. By disrupting cellular ion homeostasis
and energy metabolism, relatively low levels of membrane-asso-
ciated oxidative stress can render neurons vulnerable to excito-
toxicity and apotosis [11]. The dysfunction and degeneration of
synapses inADmay involveAβ-induced oxidative stress because
exposure of synapses toAβ impairs the function ofmembrane ion
and glutamate transporters and compromises mitochondrial
function by an oxidative-stress-mediated mechanism [11].
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43 amino acids, in the senile plaques in the AD brain is believed
to be the crucial step in AD pathogenesis (amyloid-cascade-
hypothesis), around which many of the current drug develop-
ments and clinical trials are arranged [12]. The cellular pro-
teolytic processing of an integral membrane protein of uncertain
function, amyloid precursor protein (APP), can lead to the gen-
eration of Aβ that readily form aggregates and that have neu-
rotoxic activities under certain conditions in vitro and in vivo
[13,14]. The imbalance between Aβ production and Aβ clear-
ance is the basis for the formation of amyloid plaques. The
majority of known APP and presenilin mutations responsible for
familial early onset AD affect APP processing causing over-
production of Aβ, especially Aβ(1–42) [12]. Therefore, the
amyloid-cascade-hypothesis of AD and the oxidative-stress-
hypothesis of AD have actually been united to one concept by
many groups.
A variety of compounds and antioxidants have been used to
reduce the oxidative stress associated with AD. Many of these
agents have been shown to protect cells from Aβ-induced
neurotoxicity. Moreover, several groups including ours have
reported various types of antioxidants that inhibited the formation
of fAβ from Aβ and/or destabilized β-amyloid fibrils (fAβ) both
in vitro and in vivo.
In this article, recent advances in the research on their
inhibitory effects of the formation of fAβ and destabilizing
effects of preformed fAβ are reviewed.
2. Antioxidant defense systems and antioxidants
2.1. Antioxidant defense systems: enzymes and antioxidants
The sources of ROS in nerve cells are numerous, therefore,
cells have to maintain an effective antioxidative system in order
to protect themselves against ROS overload and subsequent
damage [1]. Enzymatic and nonenzymatic antioxidants keep the
fine-tuned balance between the physiological production of
ROS and their detoxification. Superoxide radicals (O2
U−)
leaking from the oxidative phosphorylation reaction in the
mitochondria are dismutated by different types of the enzyme
superoxide dismutase to hydrogen peroxide (H2O2). The latter
is a substrate for the enzyme catalase and the intracellular
tripeptide antioxidant glutathione in conjunction with the
enzyme glutathione peroxidase. In addition, nonenzymatic
antioxidants, such as the lipophilic free radical scavenger α-
tocopherol (vitamin E), or the hydrophilic compound ascorbate
(vitamin C), the two most prominent antioxidants of their class,
can directly interact with ROS at the molecular level [15–17].
2.2. Types of antioxidants and antioxidant drugs
Four types of antioxidant activities, which are the basis for
the development of antioxidant pharmaceutical drugs can be
differentiated: (1) the inhibition of free radical formation, (2)
the direct chemical (nonenzymatic) scavenging of generated
free radicals, (3) the enzymatic detoxification of accumulating
ROS, and (4) the long-term support and induction of thecellular self-defense by initiation of gene transcription such as
inducible nitric oxide synthase (iNOS) and cyclooxygenase 2
(Cox-2) [1].
Table 1 briefly summarizes various types of antioxidant
compounds (direct, indirect, and metabolic antioxidants). The
focus is put on chemical structures and compounds that have the
potential to directly interact with ROS as a mode of antioxidant
action (direct antioxidants). The direct antioxidants are not
dependent on endogenous cellular macromolecules (e.g.,
enzymes) to exert their primary action, but they chemically
react with the damaging free radical molecules at the molecular
level. Nevertheless, to some extent, there is also interaction with
intracellular enzymes since some of these compounds are
presumed to be recycled either by endogenous oxidoreductases
directly, or indirectly via intracellular reducing shuttles such as
ascorbate or some thiols. The major class of antioxidants in the
group of direct antioxidants is the chain-breaking antioxidants.
Examples are the phenols that can be classified into two groups:
(1) monophenolic compounds, which carry one phenolic group
including tocopherol (vitamin E) and 17β-estradiol (estrogen),
and (2) polyphenolic compounds, which are usually exogenic in
contrast to the monophenolic compounds, including wine-
related polyphenols, stilbenes, and hydroquinones [1].
3. Aggregation and neurotoxicology of Aβ
3.1. Neurotoxicology of Aβ
Aβ neurotoxicity is mediated by various mechanisms ranging
from direct neurotoxic interactions with the neuronal membrane
to Aβ's effects onmembrane receptors and intracellular signaling
[1]. Interestingly, it was found that Aβ needs to be aggregated to
exert toxic activities and Aβ aggregates then directly interact with
the cell membrane [1]. It was proposed that this interaction is not
random, but is rather mediated by the receptor for advanced
glycation endproducts (RAGE) [18]. Recent studies have re-
vealed that the degree of neurotoxicity can be demonstrated with
pre-fibrillar Aβ aggregates including Aβ oligomer [19–22]. Al-
though these studies suggest that neurotoxicity and neuronal
changes associated with Aβ may stem from non-fibrillar Aβ
intermediate, an important question that remains to be answered is
whether this is also the case in the AD brain.
There is another activity of Aβ that may endanger neuronal
survival. Aβ aggregates on the nerve cell membrane have been
reported to induce a sequence of events that lead to the intra-
cellular accumulation of ROS [4,5]. Micromolar concentra-
tions of Aβ cause the oxidation of the nonsaturated
carbohydrate side chains of membrane lipids, disintegration
of the neuronal membrane and, ultimately, cell lysis [4,5].
Various additional studies by different laboratories have
supported the view that oxidative stress may be central to
the Aβ-driven neurodegeneration [1].
3.2. An in vitro model of fAβ formation
Simultaneously with other groups, we have proposed that a
nucleation-dependent polymerization model could explain the
Fig. 1. Schema of the nucleation-dependent polymerization model.
Table 1
Classification of antioxidants and mode of action
Direct antioxidants: compounds that chemically interfere with formed free
radicals
Aryl amines and indoles
Melatonin
Retinol, retinal, β-carotene, lycopene and other polyenes
Polyphenols such as wine-related polyphenols, tannic acid,
nordihydroguaiaretic acid curcumin, and rosmarinic acid
Ebselen and other selenium-containing compounds
Manganese-containing mimetics of catalase/superoxide dismutase
Tocopherol (vitamin E) and other monophenols
Rifampicin, tetracycline and doxycycline
Indirect antioxidants: compounds that prevent the formation of free radicals
Aminooxidase inhibitors
Calcium antagonists
Dopamine receptor agonists
Glutamate receptor antagonists
Nicotine
Ion chelators
Nitric oxide synthase inhibitors
Metabolic antioxidants: compounds that limit the extent of damage to the cell by
reducing the secondary metabolic burden of increased levels of free radicals
N-acetyl-cysteine, glutathione, 2-oxo-thiazolidine-4-carboxylate, and other
thiol-delivering compounds
N-butyl-α-phenylnitrone and other spin traps
Carnitine
Creatine
Lipoic acid (thioctic acid)
Ubiquinone (Coenzyme Q10) and Idebenone
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model consists of two phases, i.e., nucleation and extension
phases. Nucleus formation requires a series of association steps
of monomers that are thermodynamically unfavorable, repre-
senting the rate-limiting step in amyloid fibril formation. Once
the nucleus has been formed, further addition of monomers
becomes thermodynamically favorable, resulting in the rapid
extension of amyloid fibrils according to a first-order kinetic
model of fAβ extension, i.e., via the consecutive association of
Aβ onto the end of existing fibrils [24,27,28]. Although this
model is based on the assumption that Aβ is monomeric in the
reaction mixture, the non-fibrillar Aβ intermediate, protofibrils
suggested by Walsh et al. [20,21] and Hartley et al. [29] would
also be consistent with this model.
4. Antioxidants with anti-amyloidogenic effects
4.1. Polyphenols
4.1.1. Wine -related polyphenols
The notion that red wine may have potential health benefits
initially received a great deal of attention following the report
that moderate wine consumption was linked to a lower
incidence of coronary heart disease, an effect known as the
French paradox [30]. In addition to red wine's purported
cardioprotective effects, French and Copenhagen epidemiolog-
ical studies have suggested that moderate wine drinking may
protect against AD [31–34]. The role of ethanol itself for the
protective effect of red wine is however uncertain [35,36]. In
addition to ethanol, red wine contains a broad range ofpolyphenols that are present in the skin and seeds of grapes
[35,37–40]. Recently, several studies have suggested that many
kinds of natural polyphenols have neuroprotective effects both
in vivo and in vitro, possibly by their abilities to scavenge ROS
[41–46].
Recently, we used fluorescence spectroscopy with thioflavin
T (ThT) and electron microscopy (EM) to examine the effects of
wine-related polyphenols, myricetin (Myr), morin (Mor),
quercetin (Qur), kaempferol (Kmp), (+)-catechin (Cat) and
(−)-epicatechin (epi-Cat) on the formation, extension, and
destabilization of fAβ at pH 7.5 at 37 °C in vitro. All examined
polyphenols dose-dependently inhibited formation of fAβ from
fresh Aβ(1–40) and Aβ(1–42), as well as their extension [47].
Moreover, these polyphenols dose-dependently destabilized
preformed fAβs [47]. In cell culture experiments, Myr-treated
fAβ were suggested to be less toxic than intact fAβ, as
demonstrated by 3-[4,5 -2-yl]-2,5-diphenyltetrazolium bromide
assay [47]. The anti-amyloidogenic and fibril-destabilizing
activity of the polyphenols may be in the following order:
Myr=Mor=QurNKmpNCat=epi-Cat [47].
The structure–activity relationships of wine-related polyphe-
nols have been considered. First, Myr, Mor, Qur and Kmp have
no chirality and the hydroxyphenyl and benzopyran rings of these
molecules are located on the same plane by the rotation of the
hydroxyphenyl ring (Fig. 2). On the other hand, Cat and epi-Cat
have a chirality and the two rings cannot be located on the same
plane. This difference in the three-dimensional structure of
polyphenols may affect greatly the anti-amyloidogenic and fibril-
destabilizing activity. Second, the numbers of hydroxyl groups in
Myr, Mor, Qur and Kmp are 6, 5, 5 and 4, respectively (Fig. 2).
These numbers may also affect the activity; the more hydroxyl
groups in the molecule with the higher the anti-amyloidogenic
activity. However, there are few reports on the effects of the
polyphenols on the fAβ burden in vivo.
4.1.2. Tannic acid
Tannins (commonly referred to as tannic acid (TA)) are
water-soluble polyphenols which differ from most other natural
phenolic compounds in their ability to precipitate proteins such
as gelatin from solution [48]. This property (sometimes called
astringency) is the reason for their past and present use in the
tanning of animal skins [48]. Tannins are commonly found in a
Fig. 2. Structure of Myr, Mor, Qur, Kmp, Cat, epi-Cat, and TA.
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woody types [49]. They can accumulate in large amounts in
particular organs or tissues which can be almost any plant part:
bark, wood, leaves, fruits or roots [49]. The biological activities
of tannins include marked anti-tumor, anti-viral, inhibition of
lipid peroxidation and plasmin activity, mediation of DNA
nicking, amelioration of renal failure, and several others [50–55]. The polymeric tannins such as TA, are generally stronger
against the radicals than small molecule polyphenols, such as
Cat, Qur, and Kmp [56]. Moreover, a novel type of TA, Pista-
folia A has been reported to prevent against oxidative neuronal
cell damage [57]. In our study, TA dose-dependently inhibits
fAβ formation from fresh Aβ, and destabilizes preformed fAβ
in vitro [58]. Moreover TA exhibited much higher anti-
Fig. 3. Structure of NDGA, Cur, and RA.
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such as NDGA, Myr, RIF, and TC [58]. TA is a polymer of
phenolcarboxylic acid, gallic acid which is a part of Myr [56],
and has much more hydroxyl groups than Myr (Fig. 2). Similar
to wine-related polyphenols, TA also has been reported to have
antioxidant activity [50,56].
4.1.3. Nordihydroguaiaretic acid, curcumin, and rosmarinic
acid
Nordihydroguaiaretic acid (NDGA) is a pure compound isolated
from the creosote bush, Larrea tridentata [59]. It is a potent oxygen
radical scavenger and a lipooxygenase inhibitor [60], and has
been capable of lowering plasma glucose concentration in mouse
models of non-insulin-dependent diabetes mellitus [59].
Curcumin (Cur) is a potent antioxidant and an effective anti-
inflammatory compound [61–63]. Part of its nonsteroidal anti-
inflammatory drug-like activity is based on the inhibition of
nuclear factor κB (NFκB)-mediated transcription of inflamma-
tory cytokines [63], iNOS [64], and Cox-2 [65]. Because of
anti-tumor activity, relative safety, and its long history of use,
Cur is currently being developed for clinical use as a cancer
chemopreventive agent in India [66,67].
Rosmarinic acid (RA) is an ester of caffeic acid and 3,4-
dihydroxyphenyllaactic acid [68]. It is commonly found in
species of the Boraginaceae and the subfamily Nepetoideae of
the Lamiaceae [68], and has several interesting biological acti-
vities, e.g., antioxidant, anti-inflammatory, antimutagen, anti-
bacterial, and anti-viral [69]. The latter activity is used in the
therapy of Herpes simplex virus infections with RA-containing
extracts of Melissa officinalis. It is thought that the anti-infla-
mmatory properties are based on the inhibition of lipoxygenases
and cyclooxygenases, as well as the interference with the com-
plement cascade [69]. RA is eliminated rapidly from the blood
circulation after intravenous administration and shows very low
toxicity in mice [69].In our study, NDGA, Cur, and RA dose-dependently inhi-
bited fAβ formation from Aβ(1–40) and Aβ(1–42), their
extension, and destabilized preformed fAβs [70]. They had
similar anti-amyloidogenic activity [70]. All of these molecules
have two 3,4-dihydroxyphenyl rings (NDGA, RA) or 4-hy-
droxy-3-methoxyphenyl rings (Cur) symmetrically bound by a
short carbohydrate chain, and all the molecules are included in
polyphenol group (Fig. 3). This compact and symmetric
structure might be quite suitable for specifically binding to
free Aβ and subsequently inhibiting the polymerization of Aβ
into fAβ [70,71]. Alternatively, this structure might be suitable
for specific binding to fAβ and subsequent destabilization of the
β-sheet-rich conformation of Aβ molecules in fAβ [70,71].
Further, cell culture experiments with human embryonic kidney
293 cells indicated that fAβ destabilized by NDGA might be
less toxic than are intact fAβs [71].
In addition to our studies, several other studies suggest that
Cur, RA and NDGA could be key molecules for the devel-
opment of therapeutics for AD. Cur protects PC12 and human
umbilical vein endothelial cells from Aβ insult by strong anti-
oxidant properties [72]. NDGA interrupts the cytotoxicity of Aβ
to cultured rat hippocampal neurons, by suppressing Aβ-
induced accumulation of reactive oxygen species and intracel-
lular free Ca2+ [60]. In an in vivo study with Tg2576 APPSw
transgenic mouse, Cur suppresses inflammation and oxidative
damage in the brain, and low, nontoxic doses of Cur decrease
levels of insoluble and soluble Aβ and plaque burden in many
affected brain regions [73]. They speculated that the mechan-
isms are mainly based on the inflammation-related targets, such
as inhibition of NFκB-induced iNOS, Cox-2, and inflammatory
cytokine production [73]. Very recently, they have also shown
that Cur inhibits formation of Aβ oligomers and fibrils, binds
plaques, and reduces plaque burden in vivo [74].
4.2. Vitamins
A variety of antioxidant vitamins, such as vitamin E (DL-α-
tocopherol) [75–79], vitamin C (ascorbic acid) [5,80], and
vitamin A [81,82], have been suggested to reduce the oxidative
stress associated with AD. Recently, some groups reported that
the concentrations of vitamins A, C, E and β-carotene in
plasma, serum or cerebrospinal fluid are lower in AD patients
than in controls, suggesting that these antioxidant vitamins and
carotenoids may have been consumed as a result of excessive
production of free radicals [83–91]. Clinically, treatment with
these vitamins has been reported to delay the progression of
dementia [81,92–96].
There are several postulated mechanisms for these vitamins
to exert such effects, including protection of neurons from Aβ-
induced neurotoxicity [5,75–80]. Recently, we examined the
effects of antioxidant vitamin and carotene, vitamin A (retinol,
retinal, and retinoic acid), β-carotene, and vitamins B2, B6, C
and E on the formation, extension, and destabilization of fAβ in
vitro [97]. Among them, vitamin A and β-carotene dose-
dependently inhibited formation of fAβ from fresh Aβ, as well
as their extension [97]. Moreover, they dose-dependently de-
stabilized preformed fAβs [97]. The overall activity of the
Fig. 4. Structure of all-trans retinol, all-trans retinal, all-trans retinoic acid, and β-carotene.
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retinalNβ-caroteneN retinoic acid [97].
Preformed vitamin A (all-trans retinol and its esters) and
provitamin A (β-carotene) are essential dietary nutrients that
provide a source of retinol [98]. Both retinyl esters and β-
carotene are first metabolized to retinol. Successive oxidation of
retinol then provides retinal, which is essential for vision, and
retinoic acid, a transcription factor ligand that is important for
regulating genes involved in cell morphogenesis, differentia-
tion, and proliferation [98]. The hydroxyl group of retinol is
successively converted to the aldehyde group (retinal) and the
carboxyl group (retinoic acid). There are some interesting
structure–activity relationships. First, retinol and retinal have no
charge under physiological aqueous conditions, while retinoic
acid is negatively charged due to the terminal carboxyl group
(Fig. 4) [97]. The increase in hydrophilicity might reduce the
binding affinity of retinoic acid to Aβ or fAβ to exhibit anti-
amyloidogenic and fibril-destabilizing effects in vitro. Second,
although β-carotene has no oxygen atoms, the symmetric rod-
like structure and hydrophobicity of β-carotene would allow it
to bind to Aβ and/or fAβ to exhibit anti-amyloidogenic andfibril-destabilizing effects in vitro (Fig. 4) [97]. Interestingly,
both vitamin A and β-carotene have also been reported to have
antioxidant activity [99,100]. However, few reports that
describe the effects of the vitamins on the fAβ burden in vivo
have thus far been available except one report the neurotoxicity
Aβ(1–42) can effectively be ameliorated by administration
vitamin E and C [101].
4.3. Nicotine
Previous reports suggested an inverse relationship between
smoking and AD [102–104]. Nicotine (Fig. 5) in tobacco
brings illness to humans but in its pure form has the potential to
be a valuable pharmaceutical agent [105]. In vitro experiments
showed that nicotine might provide some of its therapeutic
actions in AD through antioxidant mechanisms [106]. Clini-
cally, nicotine administration via injection or skin patches has
been shown to significantly improve attention and learning in
animals [107], as well as in patients with AD [108–110]. These
beneficial effects of nicotine have been attributed to the
protection of neurons against Aβ toxicity via the upregulation
Fig. 5. Structure of nicotine, pyridine, methylpyrrolidine, RIF, TC, and melatonin.
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[111,112].
Nicotine at 50 μmol/L inhibits fAβ(1−42) formation from
50 μmol/L Aβ(1–42) using centrifugation and ultraviolet
spectroscopy [113]. They indirectly measured the amount of
fAβ(1–42) formed, by quantifying the concentration of soluble
Aβ(1–42) remaining in the supernatant after centrifugation. On
the other hand, we monitored the formation and disruption of
fAβ(1–40) and fAβ(1–42) directly using fluorescence spec-
troscopy with ThT and EM [114]. As a result, nicotine dose-
dependently inhibited fAβ(1–40) and fAβ(1–42) formation
from fresh Aβ(1–40) and Aβ(1–42), respectively, as well as the
extension reaction of both fAβ [114]. Moreover, nicotine des-tabilized preformed fAβ(1–40) and fAβ(1–42) [114]. These
effects of nicotine were observed at concentrations above 10
mmol/L, about 200 times higher than the effective concentration
reported by Salomon et al. (50 μmol/L). Although we have no
clear interpretation for this discrepancy, the methods to monitor
the formation and destabilization of fAβs may cause the
difference.
As for the anti-amyloidogenic mechanisms of nicotine, it
was suggested that nicotine inhibits fAβ formation probably
by binding to a small, soluble β-sheet aggregate [115]. In
our study, the anti-amyloidogenic effects of nicotine were
similar to those of N-methylpyrrolidine, indicating that the
effects of nicotine could be attributed to N-methylpyrrolidine
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consistent with the report that the binding of nicotine to
Aβ(1–28) primarily involves N-CH3 and 5′CH2 pyrrolidine
moieties of nivotine and the histidine residues of Aβ(1–28)
[113]. It has also been reported that chronic nicotine
treatment reduces Aβ deposits in the brain of Tg2576 mice
[116]. In addition, there was a selective reduction in
extractable Aβ in nicotine-treated mice; cortical insoluble
Aβ(1–40) and Aβ(1–42) levels were lower, whilst there was
no significant change in soluble Aβ(1–40) or Aβ(1–42)
levels [116].
4.4. Rifampicin and tetracyclines
Rifampicin (RIF) and tetracyclines (TCs) (Fig. 5) are
effective against the bacterium Chlamydia pneumoniae,
recognized as a common cause of upper and lower
respiratory infections and a possible cause of coronary
artery disease [117–119]. Although C. pneumoniae has been
suggested to have an etiologic role in AD [120], studies
with polymerase chain reaction detection of C. pneumoniae
in the brains of AD patients have yielded conflicting results
[120–122].
RIF and TCs have also been shown in vitro to interfere
with the accumulation of Aβ and subsequent development of
fAβ [123–125]. RIF and its derivatives, which possess a
naphthohydroquinone or naphthoquinone structure, inhibited
Aβ(1–40) aggregation and neurotoxicity in a concentration-
dependent manner, by the ThT assay and EM and cytotoxicity
assays using rat pheochromocytoma PC12 cells [123,124].
Electron spin resonance spectrometric analysis revealed that
the inhibitory activities of those agents correlated with their
radical-scavenging ability on hydroxyl free radical, which was
shown to be generated in cell-free incubation of Aβ(1–40)
[124]. These results suggest that at least one mechanism of
RIF-mediated inhibition of Aβ aggregation and neurotoxicity
involves scavenging of hydroxyl free radicals possibly by a
naphthohydroquinone ring in RIF [123,124]. Alternatively,
RIF was suggested to bind to Aβ hydrophobic interactions
between its lipophilic ansa chain and the hydrophobic region
of Aβ, thus blocking associations between Aβ molecules
[123]. Similarly, it was shown that TC and doxycycline not
only inhibited the fAβ(1–42) formation but also disassembled
the preformed fibrils in vitro [125]. We also reported that RIF
and TC have similar anti-amyloidogenic and fibril-destabilzing
effects in vitro [71,126]. Interestingly, RIF, and TCs have also
been reported to have antioxidant activity [124,127]. Clini-
cally, the 3-month course therapy of RIF and doxycycline
reduced cognitive worsening at 6 months of follow-up in
patients with mild to moderate AD in a randomized, controlled
trial [128].
4.5. Melatonin
Melatonin (Fig. 5) is a pineal hormone secreted during the
dark phase of the circadian cycle [129]. Its rhythmic synthesis
and secretion decline sharply during the aging process [129–132]. Importantly, various studies have shown that melatonin is
decreased during the aging process [129] and that patients with
AD havemore profound reductions of this substance [133–135].
Melatonin has demonstrated neuroprotective and antioxidant
properties against Aβ mediated oxidative injury in vitro [136,
137]. In addition, it has been shown that melatonin inhibits the
formation of β-sheets and amyloid fibrils in vitro by using
Fourier transform infra-red spectroscopy and EM [138,139]. In
our in vitro study, melatonin exhibited no significant destabiliz-
ing activity on preformed fAβ(1–40) and fAβ(1–42) [71]. Re-
cently, it was reported that administration of melatonin partially
inhibited the expected time-dependent elevation of total brain
Aβ levels, reduced abnormal nitration of proteins, and increased
survival in the transgenic mouse model of AD [140]. These
results suggest that melatonin can be explored as a disease-
modifying agent in AD. No controlled, double-blind studies are
currently available concerning the preventive or therapeutic
potential of melatonin in AD [140].
5. Conclusion
We reviewed several antioxidant compounds with anti-amy-
loidogenic effects. Some of these antioxidants are well tolerated,
can be applied as food supplements to treatment for dementia
and have minor side effects [81,92–96]. Further elucidation of
the relationships between the structures and anti-amyloidogenic
activities of these antioxidants is expected to lead to the
development of more potent anti-amyloidogenic compounds for
prevention and treatment of AD.
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